NCT07288112 2026-04-14DOC1021 Dendritic Cell Immunotherapy for Refractory MelanomaDiakonos Oncology CorporationPhase 1/2 Recruiting35 enrolled
NCT06470282 2026-02-18Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder CancerUniversity of California, San FranciscoPhase 1/2 Recruiting47 enrolled